| review article | Q7318358 |
| scholarly article | Q13442814 |
| P50 | author | Mary Jeanne Kreek | Q21531361 |
| P2093 | author name string | K Steven LaForge | |
| Eduardo Butelman | |||
| P2860 | cites work | Addiction and the brain: The neurobiology of compulsion and its persistence | Q22337278 |
| Single-nucleotide polymorphism in the human mu opioid receptor gene alters beta-endorphin binding and activity: possible implications for opiate addiction | Q24320057 | ||
| Molecular mechanisms of cocaine reward: combined dopamine and serotonin transporter knockouts eliminate cocaine place preference | Q24603526 | ||
| Cocaine reward models: conditioned place preference can be established in dopamine- and in serotonin-transporter knockout mice | Q24650110 | ||
| Selective inhibition of cocaine-seeking behaviour by a partial dopamine D3 receptor agonist | Q28141108 | ||
| The kappa opioid nalbuphine produces gender- and dose-dependent analgesia and antianalgesia in patients with postoperative pain | Q28146053 | ||
| U50,488, a kappa opioid receptor agonist, attenuates cocaine-induced increases in extracellular dopamine in the nucleus accumbens of rats | Q28236902 | ||
| Psychotomimesis mediated by kappa opiate receptors | Q28287612 | ||
| Cyclazocine revisited | Q28298711 | ||
| Cocaine abuse sharply reduced in an effective methadone maintenance program | Q28368155 | ||
| Laboratory measures of methylphenidate effects in cocaine-dependent patients receiving treatment | Q28369446 | ||
| Disulfiram treatment for cocaine dependence in methadone-maintained opioid addicts | Q28373528 | ||
| Effects of chronic 'Binge' cocaine administration on plasma ACTH and corticosterone levels in mice deficient in DARPP-32 | Q28373956 | ||
| Dopamine D2/D3 receptors modulate cocaine's reinforcing and discriminative stimulus effects in rhesus monkeys | Q28374214 | ||
| Effect of a selective dopamine D1 agonist (ABT-431) on smoked cocaine self-administration in humans | Q28374715 | ||
| GABAergic blockade of cocaine-associated cue-induced increases in nucleus accumbens dopamine | Q28583003 | ||
| Opiate receptor knockout mice define mu receptor roles in endogenous nociceptive responses and morphine-induced analgesia | Q28585437 | ||
| Enhanced and delayed stress-induced alcohol drinking in mice lacking functional CRH1 receptors | Q28592400 | ||
| Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats | Q29619737 | ||
| Cocaine receptors on dopamine transporters are related to self-administration of cocaine | Q29619876 | ||
| Molecular basis of long-term plasticity underlying addiction | Q29620539 | ||
| Disulfiram versus placebo for cocaine dependence in buprenorphine-maintained subjects: a preliminary trial | Q31397850 | ||
| The economic costs of heroin addiction in the United States | Q31799483 | ||
| Depot naltrexone: long-lasting antagonism of the effects of heroin in humans | Q33837599 | ||
| A double-blind, placebo-controlled study of oral nalmefene for alcohol dependence | Q33844871 | ||
| Cocaine self-administration in dopamine-transporter knockout mice | Q33858028 | ||
| Reinforcing and discriminative stimulus effects of RTI 111, a 3-phenyltropane analog, in rhesus monkeys: interaction with methamphetamine | Q33938662 | ||
| Modulation of cocaine and food self-administration by low- and high-efficacy D1 agonists in squirrel monkeys | Q33955144 | ||
| Effects of chronic administration of the D1 receptor partial agonist SKF 77434 on cocaine self-administration in rhesus monkeys | Q33958139 | ||
| RTI 113, a 3-phenyltropane analog, produces long-lasting cocaine-like discriminative stimulus effects in rats and squirrel monkeys | Q33959235 | ||
| A double-blind, placebo-controlled pilot study to evaluate the efficacy and safety of oral nalmefene HCl for alcohol dependence | Q34059254 | ||
| Effects of ecopipam, a selective dopamine D1 antagonist, on smoked cocaine self-administration by humans | Q34083204 | ||
| Self-administration of cocaine and the cocaine analog RTI-113: relationship to dopamine transporter occupancy determined by PET neuroimaging in rhesus monkeys | Q34105371 | ||
| Opioid receptor and peptide gene polymorphisms: potential implications for addictions | Q34116565 | ||
| Narcotic blockade | Q34203445 | ||
| The kappa-opioid receptor agonist U-69593 attenuates cocaine-induced behavioral sensitization in the rat. | Q44340372 | ||
| Binaltorphimine-related bivalent ligands and their kappa opioid receptor antagonist selectivity | Q44342764 | ||
| Increased mu opioid receptor binding detected by PET in cocaine-dependent men is associated with cocaine craving | Q44343960 | ||
| Prodynorphin, proenkephalin and kappa opioid receptor mRNA responses to acute "binge" cocaine | Q44344981 | ||
| Hypothalamic-pituitary-adrenal axis hypersensitivity to naloxone in opioid dependence: a case of naloxone-induced withdrawal | Q44344989 | ||
| Mu opioid receptor phosphorylation, desensitization, and ligand efficacy | Q44347204 | ||
| Mu opioid receptor gene variants: lack of association with alcohol dependence | Q44347504 | ||
| Kappa-opioid receptor blockade with nor-binaltorphimine modulates cocaine self-administration in drug-naive rats | Q44350622 | ||
| Acute intermittent morphine increases preprodynorphin and kappa opioid receptor mRNA levels in the rat brain | Q44351656 | ||
| Acute "binge" cocaine increases mu-opioid receptor mRNA levels in areas of the rat mesolimbic mesocortical dopamine system | Q44351828 | ||
| Beta endorphin levels during heroin, methadone, buprenorphine, and naloxone challenges: preliminary findings | Q44931718 | ||
| Desipramine treatment of cocaine dependence in methadone-maintained patients | Q45110517 | ||
| Auditory deprivation modifies sleep in the guinea-pig | Q46321403 | ||
| 3-4-Methylenedioxymethamphetamine-induced acute changes in dopamine transporter function | Q47816087 | ||
| Medical Safety and Side Effects of Methadone in Tolerant Individuals | Q47961561 | ||
| ‘Binge’ cocaine administration induces a sustained increase of prodynorphin mRNA in rat caudate-putamen | Q48229797 | ||
| Cocaine self-administration increases preprodynorphin, but not c-fos, mRNA in rat striatum. | Q48298508 | ||
| Nalmefene causes greater hypothalamic-pituitary-adrenal axis activation than naloxone in normal volunteers: implications for the treatment of alcoholism | Q48359259 | ||
| Cocaine self-administration differentially alters mRNA expression of striatal peptides | Q48521156 | ||
| Opioids excite dopamine neurons by hyperpolarization of local interneurons | Q48543154 | ||
| Behavioral stereotypies induced by "binge' cocaine administration are independent of drug-induced increases in corticosterone levels | Q48680422 | ||
| Imipramine treatment of cocaine abuse: possible boundaries of efficacy | Q48794595 | ||
| Neural substrates of opiate reinforcement | Q48840037 | ||
| Steady-state methadone in rats does not change mRNA levels of corticotropin-releasing factor, its pituitary receptor or proopiomelanocortin | Q48863649 | ||
| Metyrapone-induced withdrawal symptoms | Q48907448 | ||
| Acute subjective effects of dynorphin A(1-13) infusion in normal healthy subjects. | Q51091137 | ||
| Effect of dopamine receptor antagonists on cocaine subjective effects: a naturalistic case study. | Q51103486 | ||
| Effects of intravenous cocaine are partially attenuated by haloperidol. | Q51180759 | ||
| Doses of GBR12909 that suppress cocaine self-administration in non-human primates substantially occupy dopamine transporters as measured by [11C] WIN35,428 PET scans. | Q51467625 | ||
| Baclofen as a cocaine anti-craving medication: a preliminary clinical study. | Q51526312 | ||
| Baclofen attenuates the reinforcing effects of cocaine in rats. | Q51561412 | ||
| Double-blind comparison of bromocriptine and placebo in cocaine withdrawal. | Q51611582 | ||
| Treatment of Cocaine Dependence in Methadone Maintenance Clients: A Pilot Study Comparing the Efficacy of Desipramine and Amantadine | Q51701097 | ||
| Reliability of sequential naloxone challenge tests. | Q52012693 | ||
| The effects of psychosocial services in substance abuse treatment. | Q52273370 | ||
| Hypothalamic-pituitary-adrenal activity and pro-opiomelanocortin mRNA levels in the hypothalamus and pituitary of the rat are differentially modulated by acute intermittent morphine with or without water restriction stress. | Q52277626 | ||
| Pergolide mesylate for cocaine abuse: a controlled preliminary trial. | Q53930571 | ||
| Naltrexone and coping skills therapy for alcohol dependence. A controlled study | Q67587951 | ||
| A preliminary study of beta endorphin during chronic naltrexone maintenance treatment in ex-opiate addicts | Q69997055 | ||
| Circadian rhythms and levels of beta-endorphin, ACTH, and cortisol during chronic methadone maintenance treatment in humans | Q70186821 | ||
| The treatment of alcoholism in France | Q70910544 | ||
| Comparison of acamprosate and placebo in long-term treatment of alcohol dependence | Q71177254 | ||
| Relapse prevention by acamprosate. Results from a placebo-controlled study on alcohol dependence | Q71226356 | ||
| ACTH, cortisol and beta-endorphin response to metyrapone testing during chronic methadone maintenance treatment in humans | Q72413578 | ||
| Effects of E-2078, a stable dynorphin A(1-8) analog, on sedation and serum prolactin levels in rhesus monkeys | Q73257779 | ||
| Naltrexone and alcohol dependence. Role of subject compliance | Q73665563 | ||
| Naltrexone in the treatment of alcohol dependence | Q34241680 | ||
| A MEDICAL TREATMENT FOR DIACETYLMORPHINE (HEROIN) ADDICTION. A CLINICAL TRIAL WITH METHADONE HYDROCHLORIDE. | Q34260580 | ||
| Cocaine inhibition of ligand binding at dopamine, norepinephrine and serotonin transporters: a structure-activity study | Q34307279 | ||
| Compulsive drug-seeking behavior and relapse. Neuroadaptation, stress, and conditioning factors. | Q34310825 | ||
| Cocaine sensitization and craving: differing roles for dopamine and glutamate in the nucleus accumbens | Q34420279 | ||
| Behavioral neurobiology of alcohol addiction: recent advances and challenges. | Q34616149 | ||
| Nicotine addiction: insights from recent animal studies | Q34732274 | ||
| The effects of spiradoline (U-62066E), a kappa-opioid receptor agonist, on neuroendocrine function in man | Q35025817 | ||
| Opposing tonically active endogenous opioid systems modulate the mesolimbic dopaminergic pathway | Q36877274 | ||
| One-year follow-up of disulfiram and psychotherapy for cocaine-alcohol users: sustained effects of treatment | Q39550515 | ||
| Behavioral methods for the assessment of alcohol tolerance and dependence | Q39707921 | ||
| Medical complications in methadone patients | Q39787522 | ||
| An allelic variation in the human prodynorphin gene promoter alters stimulus-induced expression | Q40904223 | ||
| A multicenter trial of bupropion for cocaine dependence in methadone-maintained patients | Q40963918 | ||
| Loss of morphine-induced analgesia, reward effect and withdrawal symptoms in mice lacking the mu-opioid-receptor gene | Q41157124 | ||
| Opioid receptors: some perspectives from early studies of their role in normal physiology, stress responsivity, and in specific addictive diseases | Q41247930 | ||
| Opiate and Cocaine Addictions: Challenge for Pharmacotherapies | Q41527887 | ||
| High-dose naloxone infusions in normals. Dose-dependent behavioral, hormonal, and physiological responses | Q41556109 | ||
| Destruction of dopamine in the nucleus accumbens selectively attenuates cocaine but not heroin self-administration in rats | Q41573401 | ||
| Effects of cyclazocine on cocaine self-administration in rats | Q42538794 | ||
| Disulfiram effects on acute cocaine administration | Q42538809 | ||
| Methylphenidate treatment for cocaine abusers with adult attention-deficit/hyperactivity disorder: a pilot study | Q42540961 | ||
| Drug dependence: stress and dysregulation of brain reward pathways | Q43070756 | ||
| Altered HPA axis responsivity to metyrapone testing in methadone maintained former heroin addicts with ongoing cocaine addiction | Q43562236 | ||
| Crack cocaine--a two-year follow-up of treated patients | Q43564570 | ||
| Effectiveness of propranolol for cocaine dependence treatment may depend on cocaine withdrawal symptom severity | Q43571809 | ||
| The frequency of cocaine administration impacts cocaine-induced receptor alterations | Q43590159 | ||
| Gamma-vinyl GABA (GVG) blocks expression of the conditioned place preference response to heroin in rats. | Q43629682 | ||
| The effects of opioid peptides on dopamine release in the nucleus accumbens: an in vivo microdialysis study | Q43695146 | ||
| Reinforcing effects of D2 dopamine receptor agonists and partial agonists in rhesus monkeys | Q43728938 | ||
| Mixed kappa agonists and mu agonists/antagonists as potential pharmacotherapeutics for cocaine abuse: synthesis and opioid receptor binding affinity of N-substituted derivatives of morphinan | Q43759911 | ||
| Hypothalamic CRH mRNA levels are differentially modulated by repeated 'binge' cocaine with or without D(1) dopamine receptor blockade | Q43764432 | ||
| The circuitry mediating cocaine-induced reinstatement of drug-seeking behavior. | Q43770574 | ||
| Effect of flupenthixol on subjective and cardiovascular responses to intravenous cocaine in humans | Q43774548 | ||
| Repeated cocaine administration attenuates group I metabotropic glutamate receptor-mediated glutamate release and behavioral activation: a potential role for Homer. | Q43792467 | ||
| The mu-opioid receptor gene polymorphism (A118G) alters HPA axis activation induced by opioid receptor blockade | Q43829059 | ||
| Naltrexone decreases craving and alcohol self-administration in alcohol-dependent subjects and activates the hypothalamo-pituitary-adrenocortical axis. | Q43893915 | ||
| Cortisol levels during chronic naltrexone maintenance treatment in ex-opiate addicts | Q43897314 | ||
| Oral ethanol self-administration in rats is reduced by the administration of dopamine and glutamate receptor antagonists into the nucleus accumbens | Q43915028 | ||
| Rewarding effects of ethanol and cocaine in mu opioid receptor-deficient mice | Q43937577 | ||
| Potentially functional polymorphism in the promoter region of prodynorphin gene may be associated with protection against cocaine dependence or abuse | Q43981246 | ||
| Hypothalamic-pituitary-adrenocortical (HPA) axis response and biotransformation of oral naltrexone: preliminary examination of relationship to family history of alcoholism | Q43991017 | ||
| Chronic cocaine alters brain mu opioid receptors | Q44331495 | ||
| Morphine self-administration in mu-opioid receptor-deficient mice | Q44332170 | ||
| Kappa opioid inhibition of morphine and cocaine self-administration in rats | Q44333113 | ||
| Treatment of opioid-induced constipation with oral naloxone: A pilot study | Q44333656 | ||
| Association between mu opioid receptor gene polymorphisms and Chinese heroin addicts | Q44335420 | ||
| Repeated cocaine administration upregulates kappa and mu, but not delta, opioid receptors. | Q44335466 | ||
| Differential effects of systemically administered nor-binaltorphimine (nor-BNI) on kappa-opioid agonists in the mouse writhing assay | Q44335990 | ||
| P433 | issue | 9 | |
| P921 | main subject | pharmacotherapy | Q701216 |
| P304 | page(s) | 710-726 | |
| P577 | publication date | 2002-09-01 | |
| P1433 | published in | Nature Reviews Drug Discovery | Q45998 |
| P1476 | title | Pharmacotherapy of addictions | |
| P478 | volume | 1 |
| Q89471445 | "My life is under control with these medications": an interpretative phenomenological analysis of managing chronic pain with opioids |
| Q41496120 | 1-Substituted 4-(3-Hydroxyphenyl)piperazines Are Pure Opioid Receptor Antagonists |
| Q37422855 | A functional haplotype implicated in vulnerability to develop cocaine dependence is associated with reduced PDYN expression in human brain |
| Q44341058 | A phase 2, placebo-controlled study of the opioid receptor antagonist LY2196044 for the treatment of alcohol dependence |
| Q37267671 | A rare case of dicyclomine abuse |
| Q35023045 | Acetylcholine enhancement in the nucleus accumbens prevents addictive behaviors of cocaine and morphine |
| Q43639345 | Acute effects of heroin on emotions in heroin-dependent patients |
| Q42949302 | Acute effects of sublingual buprenorphine on brain responses to heroin-related cues in early-abstinent heroin addicts: an uncontrolled trial |
| Q37027306 | Acute withdrawal from chronic escalating-dose binge cocaine administration alters kappa opioid receptor stimulation of [35S] guanosine 5'-O-[gamma-thio]triphosphate acid binding in the rat ventral tegmental area |
| Q44438204 | Acute ‘binge’ cocaine administration elevates dynorphin mRNA in the caudate putamen of C57BL/6J but not 129/J mice |
| Q38080576 | Addiction and corticotropin-releasing hormone type 1 receptor antagonist medications |
| Q28270110 | Agents in development for the management of cocaine abuse |
| Q28087404 | Agonist Medications for the Treatment of Cocaine Use Disorder |
| Q35195803 | Alcohol and opioid dependence medications: prescription trends, overall and by physician specialty |
| Q51872493 | An 18-year follow-up of patients admitted to methadone treatment for the first time. |
| Q37580649 | An Essential Role for Adenosine Signaling in Alcohol Abuse |
| Q90027693 | Association of opioid receptor gene polymorphisms with drinking severity and impulsivity related to alcohol use disorder in a Korean population |
| Q36762016 | Association of polymorphisms in the melanocortin receptor type 2 (MC2R, ACTH receptor) gene with heroin addiction |
| Q38655315 | Atg5- and Atg7-dependent autophagy in dopaminergic neurons regulates cellular and behavioral responses to morphine |
| Q34468303 | Big dynorphin, a prodynorphin-derived peptide produces NMDA receptor-mediated effects on memory, anxiolytic-like and locomotor behavior in mice |
| Q35585627 | Bingeing rats: a model of intermittent excessive behavior? |
| Q36900049 | Black cohosh (Actaea racemosa, Cimicifuga racemosa) behaves as a mixed competitive ligand and partial agonist at the human mu opiate receptor |
| Q36232833 | Buprenorphine-elicited alteration of adenylate cyclase activity in human embryonic kidney 293 cells coexpressing κ-, μ-opioid and nociceptin receptors. |
| Q37722356 | Buprenorphine-naloxone therapy in pain management |
| Q37075089 | CYP2B6 SNPs are associated with methadone dose required for effective treatment of opioid addiction |
| Q36928874 | Can the chronic administration of the combination of buprenorphine and naloxone block dopaminergic activity causing anti-reward and relapse potential? |
| Q44660002 | Central administration of nociceptin/orphanin FQ blocks the acquisition of conditioned place preference to morphine and cocaine, but not conditioned place aversion to naloxone in mice |
| Q36143981 | Chromatin alterations in response to forced swimming underlie increased prodynorphin transcription |
| Q41458616 | Chronic Nicotine Exposure Initiated in Adolescence and Unpaired to Behavioral Context Fails to Enhance Sweetened Ethanol Seeking |
| Q45213812 | Clock reset for alcoholism |
| Q36085085 | Combining research approaches to advance our understanding of drug addiction. |
| Q37142229 | Critical issues in the treatment of hepatitis C virus infection in methadone maintenance patients |
| Q35143623 | Current perspectives on selective dopamine D(3) receptor antagonists as pharmacotherapeutics for addictions and related disorders |
| Q34030618 | Decision-making in stimulant and opiate addicts in protracted abstinence: evidence from computational modeling with pure users |
| Q37383571 | Development of pharmacotherapies for drug addiction: a Rosetta stone approach |
| Q35243402 | Differential pharmacological actions of methadone and buprenorphine in human embryonic kidney 293 cells coexpressing human μ-opioid and opioid receptor-like 1 receptors. |
| Q30436776 | Discovery of N-{4-[(3-hydroxyphenyl)-3-methylpiperazin-1-yl]methyl-2-methylpropyl}-4-phenoxybenzamide analogues as selective kappa opioid receptor antagonists |
| Q30486052 | Disruption of the CRF(2) receptor pathway decreases the somatic expression of opiate withdrawal. |
| Q33700033 | Distinct patterns of neural activation associated with ethanol seeking: effects of naltrexone |
| Q35751195 | Dopamine in drug abuse and addiction: results from imaging studies and treatment implications |
| Q24656085 | Dopamine transport inhibitors based on GBR12909 and benztropine as potential medications to treat cocaine addiction |
| Q37798319 | Dopaminergic reward system: a short integrative review |
| Q44335721 | Downregulation of kappa-opioid receptors in basolateral amygdala and septum of rats withdrawn for 14 days from an escalating dose "binge" cocaine administration paradigm |
| Q38196319 | Drug abstinence: exploring animal models and behavioral treatment strategies |
| Q34575484 | Drug addiction. |
| Q35954309 | Drug addiction: the neurobiology of behaviour gone awry |
| Q33643136 | Drug-induced and genetic alterations in stress-responsive systems: Implications for specific addictive diseases |
| Q44344098 | Effect of the endogenous kappa opioid agonist dynorphin A(1-17) on cocaine-evoked increases in striatal dopamine levels and cocaine-induced place preference in C57BL/6J mice |
| Q44344105 | Effect of the kappa opioid agonist R-84760 on cocaine-induced increases in striatal dopamine levels and cocaine-induced place preference in C57BL/6J mice |
| Q36083896 | Effects of environmental enrichment on the incubation of cocaine craving. |
| Q34033791 | Effects of extended cocaine access and cocaine withdrawal on choice between cocaine and food in rhesus monkeys |
| Q44350757 | Effects of high-dose methadone maintenance on cocaine place conditioning, cocaine self-administration, and mu-opioid receptor mRNA expression in the rat brain |
| Q35027648 | Effects of the novel, selective and low-efficacy mu opioid receptor ligand NAQ on intracranial self-stimulation in rats |
| Q60632732 | Eficacia clínica de la buprenorfina |
| Q60632721 | Eficacia y manejo clínico de la buprenorfina |
| Q35969069 | Elevated Hair Cortisol Levels among Heroin Addicts on Current Methadone Maintenance Compared to Controls |
| Q34461542 | Endogenous kappa-opioid receptor systems regulate mesoaccumbal dopamine dynamics and vulnerability to cocaine |
| Q35581558 | Endogenous opiates and behavior: 2002 |
| Q24614016 | Evidence-based practices for substance use disorders |
| Q30276911 | Exercise during early, but not late abstinence, attenuates subsequent relapse vulnerability in a rat model |
| Q37027238 | Extreme marginalization: addiction and other mental health disorders, stigma, and imprisonment |
| Q94089588 | Fabrication of Unimolecular Double-stranded DNA Microarrays on Solid Surfaces for Probing DNA-Protein/Drug Interactions |
| Q52316006 | From gene networks to drugs: systems pharmacology approaches for AUD. |
| Q35682961 | Genes associated with addiction: alcoholism, opiate, and cocaine addiction |
| Q34463235 | Genetic influences on impulsivity, risk taking, stress responsivity and vulnerability to drug abuse and addiction |
| Q40367486 | Genome-wide association study of therapeutic opioid dosing identifies a novel locus upstream of OPRM1. |
| Q37973031 | Gestational restraint stress and the developing dopaminergic system: an overview. |
| Q48507105 | Glucocorticoid negative feedback in methadone-maintained former heroin addicts with ongoing cocaine dependence: dose-response to dexamethasone suppression |
| Q48709433 | High methadone dose significantly reduces cocaine use in methadone maintenance treatment (MMT) patients |
| Q34033200 | Human behavioral pharmacology, past, present, and future: symposium presented at the 50th annual meeting of the Behavioral Pharmacology Society |
| Q35540682 | Identifying candidate drivers of alcohol dependence-induced excessive drinking by assembly and interrogation of brain-specific regulatory networks |
| Q36101368 | Imaging addiction with PET: is insight in sight? |
| Q36633126 | Imaging of opioid receptors in the central nervous system |
| Q31113208 | Imaging the addicted human brain |
| Q39181057 | Incarcerated intravenous heroin users: predictors of post-release utilization of methadone maintenance treatment. |
| Q44347200 | Increased attributable risk related to a functional mu-opioid receptor gene polymorphism in association with alcohol dependence in central Sweden |
| Q37728032 | Inhibitory role of oxytocin in psychostimulant-induced psychological dependence and its effects on dopaminergic and glutaminergic transmission |
| Q48180283 | Interest for delivery of cocaethylene in a sustained release emulsion vs saline evaluated on behavioral sensitization in naive and cocaine-sensitized mice |
| Q24647849 | Kappa opioids as potential treatments for stimulant dependence |
| Q58582823 | MemBrain: An Easy-to-Use Online Webserver for Transmembrane Protein Structure Prediction |
| Q57360794 | Membrane leakage induced by dynorphins |
| Q38537599 | Methadone Medical Maintenance: An Early 21st-Century Perspective |
| Q28478509 | Mitragynine attenuates withdrawal syndrome in morphine-withdrawn zebrafish |
| Q27008450 | Molecular, cellular, and structural mechanisms of cocaine addiction: a key role for microRNAs |
| Q34478208 | N-substituted cis-4a-(3-hydroxyphenyl)-8a-methyloctahydroisoquinolines are opioid receptor pure antagonists |
| Q36762428 | Naloxone treatment in opioid addiction: the risks and benefits |
| Q37355904 | Natural products as tools for neuroscience: discovery and development of novel agents to treat drug abuse |
| Q50656042 | Negative reinforcement via motivational withdrawal is the driving force behind the transition to addiction. |
| Q35087543 | Nerve growth factor β polypeptide (NGFB) genetic variability: association with the methadone dose required for effective maintenance treatment |
| Q37496856 | Neurocognitive and neuroinflammatory correlates of PDYN and OPRK1 mRNA expression in the anterior cingulate in postmortem brain of HIV-infected subjects |
| Q44494962 | Neuromorphological background of cannabis addiction |
| Q35183957 | Neuropeptides: opportunities for drug discovery |
| Q24634249 | Neurotensin receptor antagonist administered during cocaine withdrawal decreases locomotor sensitization and conditioned place preference |
| Q28302782 | New developments in the pharmacotherapy of cocaine abuse |
| Q37897596 | Novel neuropeptides as ligands of orphan G protein-coupled receptors |
| Q36633730 | On blending practice and research: the search for commonalities in substance abuse treatment |
| Q49270407 | Opiate Drugs with Abuse Liability Hijack the Endogenous Opioid System to Disrupt Neuronal and Glial Maturation in the Central Nervous System |
| Q36499673 | Opiate addiction and cocaine addiction: underlying molecular neurobiology and genetics |
| Q35763921 | Opiate addiction therapies and HIV-1 Tat: interactive effects on glial [Ca²⁺]i, oxyradical and neuroinflammatory chemokine production and correlative neurotoxicity. |
| Q37341893 | Opiate and cocaine addiction: from bench to clinic and back to the bench |
| Q44341308 | Opioid precursor protein isoform is targeted to the cell nuclei in the human brain |
| Q30476288 | Oral methylphenidate normalizes cingulate activity in cocaine addiction during a salient cognitive task |
| Q38233865 | Orquestic regulation of neurotransmitters on reward-seeking behavior. |
| Q35203770 | Pharmacogenomics of alcohol response and addiction |
| Q35454866 | Pharmacologic treatments for opioid dependence: detoxification and maintenance options |
| Q33914167 | Pharmacotherapy in the treatment of addiction: methadone |
| Q36751967 | Pharmacotherapy of dual substance abuse and dependence |
| Q26992051 | Positron emission tomography molecular imaging of dopaminergic system in drug addiction |
| Q35691213 | Preclinical Assessment of Lisdexamfetamine as an Agonist Medication Candidate for Cocaine Addiction: Effects in Rhesus Monkeys Trained to Discriminate Cocaine or to Self-Administer Cocaine in a Cocaine Versus Food Choice Procedure |
| Q48527278 | Predictors for dropping-out from methadone maintenance therapy programs among heroin users in southern Taiwan |
| Q46251268 | Prodynorphin gene promoter repeat associated with cocaine/alcohol codependence |
| Q36804132 | Punishment induces risky decision-making in methadone-maintained opiate users but not in heroin users or healthy volunteers |
| Q30438149 | Recent advances in the development of treatments for alcohol and cocaine dependence: focus on topiramate and other modulators of GABA or glutamate function |
| Q44340927 | Receptor-selective changes in mu-, delta- and kappa-opioid receptors after chronic naltrexone treatment in mice |
| Q38600702 | Repeated Administration of Opra Kappa (LY2456302), a Novel, Short-Acting, Selective KOP-r Antagonist, in Persons with and Without Cocaine Dependence |
| Q47876948 | Research with Older Adult Methadone Clients: The Importance of Monitoring Suicide Ideation |
| Q36526582 | Responses to novelty and vulnerability to cocaine addiction: contribution of a multi-symptomatic animal model |
| Q37103624 | Role of a functional human gene polymorphism in stress responsivity and addictions |
| Q35792661 | Role of acetylcholine transmission in nucleus accumbens and ventral tegmental area in heroin-seeking induced by conditioned cues |
| Q45056291 | Role of d-amphetamine and d-methamphetamine as active metabolites of benzphetamine: Evidence from drug discrimination and pharmacokinetic studies in male rhesus monkeys |
| Q36739205 | Role of phenmetrazine as an active metabolite of phendimetrazine: evidence from studies of drug discrimination and pharmacokinetics in rhesus monkeys |
| Q35120472 | Role of the ventral tegmental area in methamphetamine extinction: AMPA receptor-mediated neuroplasticity |
| Q37160674 | Search for genetic markers and functional variants involved in the development of opiate and cocaine addiction and treatment |
| Q36149174 | Self-administration of cannabinoids by experimental animals and human marijuana smokers |
| Q52307616 | Sensitive determination of methadone in human serum and urine by dispersive liquid-liquid microextraction based on the solidification of a floating organic droplet followed by HPLC-UV. |
| Q40741139 | Specific and nonspecific effects of naltrexone on goal-directed and habitual models of alcohol seeking and drinking. |
| Q36799030 | Statins Reduce the Risks of Relapse to Addiction in Rats |
| Q30480561 | Steady-state methadone blocks cocaine seeking and cocaine-induced gene expression alterations in the rat brain |
| Q24629577 | Stress, dysregulation of drug reward pathways, and the transition to drug dependence |
| Q40227077 | Structural determinants of opioid activity in derivatives of 14-aminomorphinones: effects of changes to the chain linking of the C14-amino group to the aryl ring |
| Q90234496 | Substance Use Disorder, Intravenous Injection, and HIV Infection: A Review |
| Q44344913 | Substantial attributable risk related to a functional mu-opioid receptor gene polymorphism in association with heroin addiction in central Sweden |
| Q40565281 | Successful Anti-HCV Therapy of a Former Intravenous Drug User with Sofosbuvir and Daclatasvir in a Peritranspant Setting: A Case Report. |
| Q36343383 | Targeted exosome-mediated delivery of opioid receptor Mu siRNA for the treatment of morphine relapse |
| Q36309741 | The "ups and downs" of signaling cascades in addiction |
| Q33937819 | The GABAB receptor agonist baclofen administered into the median and dorsal raphe nuclei is rewarding as shown by intracranial self-administration and conditioned place preference in rats |
| Q30794301 | The addicted human brain: insights from imaging studies |
| Q48315524 | The effects of buprenorphine on fentanyl withdrawal in rats |
| Q36110480 | The endogenous opioid system in cocaine addiction: what lessons have opioid peptide and receptor knockout mice taught us? |
| Q38479752 | The epigenetic regulation of the opioid system: new individualized prompt prevention and treatment strategies. |
| Q37040492 | The genetics of the opioid system and specific drug addictions |
| Q48686580 | The impact of diacetylmorphine on hypothalamic-pituitary-adrenal axis activity and heroin craving in heroin dependence |
| Q28236333 | The neurocircuitry of illicit psychostimulant addiction: acute and chronic effects in humans |
| Q44343876 | The opioid antagonist naltrexone reduces the reinforcing effects of Delta 9 tetrahydrocannabinol (THC) in squirrel monkeys |
| Q40079119 | The single nucleotide polymorphism A118G alters functional properties of the human mu opioid receptor |
| Q37100946 | Tissue plasminogen activator modulates the cellular and behavioral response to cocaine. |
| Q42157707 | Tissue-specific DNA methylation of the human prodynorphin gene in post-mortem brain tissues and PBMCs |
| Q36906670 | Translational research in medication development for nicotine dependence |
| Q40521596 | Treating drug using prison inmates with auricular acupuncture: a randomized controlled trial |
| Q42220594 | Trends in substance abuse and infectious disease over 20 years in a large methadone maintenance treatment (MMT) clinic in Israel |
| Q37182956 | Voluntary alcohol drinking enhances proopiomelanocortin gene expression in nucleus accumbens shell and hypothalamus of Sardinian alcohol-preferring rats |
| Q24642144 | Zyklophin, a systemically active selective kappa opioid receptor peptide antagonist with short duration of action |
| Q26864309 | κ-opioid receptor/dynorphin system: genetic and pharmacotherapeutic implications for addiction |
Search more.